Mundipharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus

Lead Product(s): Povidone-Iodine

Therapeutic Area: Infections and Infectious Diseases Product Name: Betadine

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

Testing has demonstrated BETADINE's® strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: BETADINE® antiseptic products, Skin Cleanser, Gargle and Mouthwash and Throat Spray.

Mundipharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Mundipharma Gets E.C Approval for Extended Invokana® (Canagliflozin) Indication to Cover Diabetic KD in Type 2 Diabetes

Lead Product(s): Canagliflozin

Therapeutic Area: Nephrology Product Name: Invokana

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 03, 2020

Details:

The EC approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which achieved pre-specified efficacy criterion.

Mundipharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan

Lead Product(s): Adalimumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Samsung Bioepis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 16, 2020

Details:

The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).

Mundipharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Mundipharma, Biosolution to market CartiLife in South Korea

Lead Product(s): Chondrocytes

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Biosolution

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 06, 2020

Details:

Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.

Find

Find Clinical Drug Pipeline Developments & Deals by Mundipharma

Pipeline Prospector Find Drug Development Pipeline & Deal Updates

Companies By Therapeutic Area

Development Status

Mundipharma

Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus

Mundipharma

Mundipharma Gets E.C Approval for Extended Invokana® (Canagliflozin) Indication to Cover Diabetic KD in Type 2 Diabetes

Mundipharma

Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan

Mundipharma

Mundipharma, Biosolution to market CartiLife in South Korea